Skip to content

CareDx CDNA Lease Liability Payments - Due Year Four

Lease Liability Payments - Due Year Four at other companies

Veracyte logo
VeracyteVCYT
$7.06M-14.4%
Abbott logo
AbbottABT
$151M+12.7%
BillionToOne, Inc.
 logo
BillionToOne, Inc. BLLN
$10.09M
Natera, Inc. logo
Natera, Inc.NTRA
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
Guardant Health logo
Guardant HealthGH

Other financials

Income statement

See full
Revenue$117.7M+39.0%
Operating income$1.2M+109%
Net income$2.8M+127%
EPS (diluted)$0.05+126%

Balance sheet

See full
Cash & equivalents$78.5M-12.1%
Total debt$24.5M-19.1%
Total equity$313.5M-17.3%
Total assets$411.1M-16.0%

Cash flow

See full
Operating cash flow$4.3M+116%
CapEx$3.8M+134%
Free cash flow$514.0K+102%

Valuation

See full
Market cap$1.4B+32.2%
Enterprise value$1.35B+34.6%
P/S3.4×+0.3×

Profitability

See full
Gross margin65.5%
Operating margin-3.9%-18.3pp
Net margin-2%-19.9pp
FCF margin-0%0.0pp

Returns & leverage

See full
Return on equity-2.4%-21.9pp
Debt / equity0.1×0.0×
Current ratio3.4×-0.7×

Where this comes from

Reported directly by CareDx in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour.

The official record: CareDx’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about CareDx's lease liability payments - due year four.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CareDx's lease liability payments - due year four?
CareDx (CDNA) reported lease liability payments - due year four of $1.73M in Q1 2026.
How has CareDx's lease liability payments - due year four changed year-over-year?
CareDx's lease liability payments - due year four decreased by 30.7% year-over-year, from $2.5M to $1.73M.
What does lease liability payments - due year four mean?
The contractual cash obligations for operating and finance leases due in the fourth year following the balance sheet date. This is part of the long-term lease maturity schedule that helps investors assess the company's future fixed cost burden. It allows for better modeling of long-term capital allocation and cash flow stability.